Since SRSF1 reduction promotes autophagy initiation and inhibits Gefitinib-resistant cancer cell progression and tumorigenesis partially through suppressing splicing of Bcl-xL, we tested if co-expression of Bcl-xL could overturn SRSF1-knockdown-induced tumor suppression in Gefitinib-resistant cancer cells. This evidence concerns the gene BCL2L1 and cancer.